<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020369</url>
  </required_header>
  <id_info>
    <org_study_id>RB-FVIIa-006-13</org_study_id>
    <nct_id>NCT02020369</nct_id>
  </id_info>
  <brief_title>Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors</brief_title>
  <official_title>A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>rEVO Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>rEVO Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate
      dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the
      treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor
      VIII/IX
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a global, multicenter, Phase III, prospective, open-label, randomized, crossover
      study. After obtaining informed consent and performance of screening procedures, patients who
      met all inclusion and exclusion criteria were randomized to one of two treatment regimens as
      follows:

        -  75 µg/kg treatment regimen

        -  225 µg/kg treatment regimen

      For each treatment regimen there were two phases:

        -  Phase A (Initial phase)

        -  Phase B (Treatment phase)

      The assigned treatment regimen was the dose administered in Phase A and was the starting dose
      in Phase B.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Successfully Treated Mild/Moderate Bleeding Episodes</measure>
    <time_frame>12 hours after first administration of study drug</time_frame>
    <description>For the primary efficacy endpoint, successful treatment of a bleeding episode was defined as a combination of the following:
&quot;Good&quot; or &quot;Excellent&quot; response noted by the patient
Study drug treatment: No further treatment with study drug beyond timepoint for this bleeding episode
No other hemostatic treatment needed for this bleeding episode
No administration of blood products that would indicate continuation of bleeding beyond timepoint
No increase of pain beyond timepoint that could not otherwise be explained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported &quot;Good&quot; or &quot;Excellent&quot; Responses at 12 Hours</measure>
    <time_frame>at 12 hours</time_frame>
    <description>Based on Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; responses as per the below descriptions:
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Assessment of a &quot;Good&quot; or &quot;Excellent&quot; Response of Mild/Moderate Bleeding Episodes by the Patient</measure>
    <time_frame>Within 24 hours of Bleeding Episode</time_frame>
    <description>Categories of Response to Treatment are Described as Follows:
None: No noticeable effect of the treatment on the bleed or worsening of patient's condition. Continuation of treatment with the study drug was needed.
Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode</measure>
    <time_frame>Within 24 hours of Bleeding Episode</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode</measure>
    <time_frame>Through study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hemophilia A With Inhibitors</condition>
  <condition>Hemophilia B With Inhibitors</condition>
  <arm_group>
    <arm_group_label>FVIIa: 75 µg/kg first, then 225 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FVIIa: 225 µg/kg first, then 75 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Coagulation Factor VIIa (Recombinant)</intervention_name>
    <description>A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX</description>
    <arm_group_label>FVIIa: 75 µg/kg first, then 225 µg/kg</arm_group_label>
    <arm_group_label>FVIIa: 225 µg/kg first, then 75 µg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be male with a diagnosis of congenital hemophilia A and/or B of any severity

          -  have one of the following:

          -  a positive inhibitor test Bethesda Unit (BU) ≥ 5 (as confirmed at screening by the
             institutional lab), OR

          -  a BU&lt;5 but expected to have a high anamnestic response to FVIII or FIX, as
             demonstrated from the subject's medical history, precluding the use of Factor VIII or
             IX products to treat bleedings, OR

          -  a BU&lt;5 but expected to be refractory to increased dosing of FVIII or FIX, as
             demonstrated from the subject's medical history, precluding the use of Factor VIII or
             IX products to treat bleedings

          -  be 12 years or older, up to and including 75 years of age (NOTE: different age
             restrictions may apply per local regulation and/or ethical considerations)

          -  have at least 3 bleeding episodes of any severity in the past 6 months be capable of
             understanding and willing to comply with the conditions of the protocol

          -  have read, understood and provided written informed consent (patient and/or
             parent(s)/legal guardian(s) if &lt;18 years of age)

        Exclusion Criteria:

          -  have any coagulation disorder other than hemophilia A or B

          -  be immuno-suppressed (i.e., the patient should not be receiving systemic
             immunosuppressive medication, cluster of differentiation 4 (CD4) counts at screening
             should be &gt;200/µl)

          -  have a known allergy or hypersensitivity to rabbits

          -  have platelet count &lt;100,000/mL

          -  have had within one month prior to first administration of the study drug in this
             study a major surgical procedure (e.g. orthopedic, abdominal)

          -  have received an investigational drug within 30 days of the first study drug
             administration, or is expected to receive such drug during participation in this study

          -  have a clinically relevant hepatic (AST and/or alanine aminotransferase (ALT) &gt;3 times
             the upper limit of normal) and/or renal impairment (creatinine &gt;2 times the upper
             limit of normal)

          -  have a history of arterial and/or venous thromboembolic events (such as myocardial
             infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or
             pulmonary embolism) within 2 years prior to first dose of study drug, or current New
             York Heart Association (NYHA) functional classification score of stage II -IV

          -  have an active malignancy (those with non-melanoma skin cancer are allowed)

          -  have any life-threatening disease or other disease or condition which, according to
             the investigator's judgment, could imply a potential hazard to the patient, interfere
             with the trial participation or trial outcome (e.g., a history of non-responsiveness
             to bypassing products).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Francois Schved, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Eloi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopaedic Hemophilia Treatment Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hemophilia and Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Research Center for Radiation Medicine and Human Ecology</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Hematological Diseases</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD HEMA</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center, Tel-hashomer hospital</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5261</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusion Medicine</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandor SRL</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Outpatient Clinic #37</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #9</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine of Academy of Medical Sciences of Ukraine</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire Hospital, Hemophilia, Hemostasis and Thrombosis Center</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <results_first_submitted>July 12, 2016</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FVIIa: 225 µg/kg First, Then 75 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant) : First Intervention (3 months), Second Intervention (3 months), repeat sequence for entirety of study.</description>
        </group>
        <group group_id="P2">
          <title>FVIIa: 75 µg/kg First, Then 225 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant): Coagulation Factor VIIa (Recombinant) : First Intervention (3 months), Second Intervention (3 months), repeat sequence for entirety of study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FVIIa 75 µg/kg First, Then 225 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), continue cycle until end of study.</description>
        </group>
        <group group_id="B2">
          <title>FVIIa 225 µg/kg First, Then 75 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), continue cycle until end of study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" spread="12.10"/>
                    <measurement group_id="B2" value="30.1" spread="12.98"/>
                    <measurement group_id="B3" value="31.0" spread="12.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male (n)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Successfully Treated Mild/Moderate Bleeding Episodes</title>
        <description>For the primary efficacy endpoint, successful treatment of a bleeding episode was defined as a combination of the following:
“Good” or “Excellent” response noted by the patient
Study drug treatment: No further treatment with study drug beyond timepoint for this bleeding episode
No other hemostatic treatment needed for this bleeding episode
No administration of blood products that would indicate continuation of bleeding beyond timepoint
No increase of pain beyond timepoint that could not otherwise be explained</description>
        <time_frame>12 hours after first administration of study drug</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa 225µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Successfully Treated Mild/Moderate Bleeding Episodes</title>
          <description>For the primary efficacy endpoint, successful treatment of a bleeding episode was defined as a combination of the following:
“Good” or “Excellent” response noted by the patient
Study drug treatment: No further treatment with study drug beyond timepoint for this bleeding episode
No other hemostatic treatment needed for this bleeding episode
No administration of blood products that would indicate continuation of bleeding beyond timepoint
No increase of pain beyond timepoint that could not otherwise be explained</description>
          <population>Treated Population</population>
          <units>Proportion of Success of BEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".849" lower_limit=".740" upper_limit=".957"/>
                    <measurement group_id="O2" value=".932" lower_limit=".881" upper_limit=".983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported “Good” or “Excellent” Responses at 12 Hours</title>
        <description>Based on Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; responses as per the below descriptions:
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
        <time_frame>at 12 hours</time_frame>
        <population>Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa: 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa: 225 µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported “Good” or “Excellent” Responses at 12 Hours</title>
          <description>Based on Patient-Reported &quot;Good&quot; or &quot;Excellent&quot; responses as per the below descriptions:
Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
          <population>Treated Population</population>
          <units>Pt-reported proportion success of BEs</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes (BEs)</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes (BEs)</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.857" lower_limit="0.750" upper_limit="0.964"/>
                    <measurement group_id="O2" value="0.937" lower_limit="0.888" upper_limit="0.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Assessment of a “Good” or “Excellent” Response of Mild/Moderate Bleeding Episodes by the Patient</title>
        <description>Categories of Response to Treatment are Described as Follows:
None: No noticeable effect of the treatment on the bleed or worsening of patient’s condition. Continuation of treatment with the study drug was needed.
Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
        <time_frame>Within 24 hours of Bleeding Episode</time_frame>
        <population>Treated Population with non-missing measurements</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa: 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa: 225 µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Assessment of a “Good” or “Excellent” Response of Mild/Moderate Bleeding Episodes by the Patient</title>
          <description>Categories of Response to Treatment are Described as Follows:
None: No noticeable effect of the treatment on the bleed or worsening of patient’s condition. Continuation of treatment with the study drug was needed.
Moderate: Some effect of the treatment on the bleed was noticed, e.g., pain decreased or bleeding signs improved, but bleed continued and required continued treatment with the study drug. Good: Symptoms of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage) had largely been reduced by the treatment, but had not completely disappeared. Symptoms had improved enough to not require more infusions of the study drug.
Excellent: Full relief of pain and cessation of objective signs of bleed (e.g., swelling, tenderness, and decreased range of motion in the case of musculoskeletal haemorrhage). No additional infusion of study drug was required.</description>
          <population>Treated Population with non-missing measurements</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Bleeding Episodes with event</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes with event</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" lower_limit="5.95" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3.00">The confidence interval (CI) for the median time is a pointwise CI. The median was 3 hours and approximately 30% of bleeding episodes had good/excellent response exactly at 3 hours which made the confidence limits non-calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode</title>
        <time_frame>Within 24 hours of Bleeding Episode</time_frame>
        <population>Treated Population with non-missing measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Factor VIIa: 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa: 225 µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode</title>
          <population>Treated Population with non-missing measurements</population>
          <units>Number of Administrations of Study Drug</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Bleeding episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.75"/>
                    <measurement group_id="O2" value="1.4" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode</title>
        <time_frame>Through study completion</time_frame>
        <population>Treated Population with non-missing measurements</population>
        <group_list>
          <group group_id="O1">
            <title>FVIIa: 75 µg/kg</title>
            <description>75 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
          <group group_id="O2">
            <title>FVIIa: 225 µg/kg</title>
            <description>225 µg/kg Treatment Regimen at Time of Mild/Moderate Bleeding Episode</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode</title>
          <population>Treated Population with non-missing measurements</population>
          <units>µg/kg per bleeding episode</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Bleeding Episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.868" spread="131.7982"/>
                    <measurement group_id="O2" value="252.963" spread="78.9732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected 2 years, 3 months, 2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coagulation Factor VIIa (Recombinant): 75 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant): 75 µg/kg for 3 months
Coagulation Factor VIIa (Recombinant): A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX</description>
        </group>
        <group group_id="E2">
          <title>Coagulation Factor VIIa (Recombinant): 225 µg/kg</title>
          <description>Coagulation Factor VIIa (Recombinant) : 225 µg/kg for 3 months
Coagulation Factor VIIa (Recombinant): A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>acute tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffry Lawrence, MD, Vice President, Clinical Development</name_or_title>
      <organization>LFB USA Inc.</organization>
      <phone>+1.508.370.5113</phone>
      <email>jeffry.lawrence@lfb-usa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

